Okamura T, Kitagawa N, Kitagawa N, Sakai K, Sumi M, Kobayashi G
J Clin Biochem Nutr. 2025; 76(1):64-84.
PMID: 39896168
PMC: 11782777.
DOI: 10.3164/jcbn.24-86.
Rathore D, Chauhan P, Bonagiri A, Gandhi L, Maisnam D, Kumar R
Heliyon. 2024; 10(21):e39941.
PMID: 39568852
PMC: 11577203.
DOI: 10.1016/j.heliyon.2024.e39941.
Aiello A, Ruggieri S, Navarra A, Tortorella C, Vanini V, Haggiag S
Vaccines (Basel). 2024; 12(8).
PMID: 39204049
PMC: 11359508.
DOI: 10.3390/vaccines12080926.
Klinmalai C, Srisala S, Sahakijpicharn T, Apiwattanakul N
Health Sci Rep. 2024; 7(7):e2250.
PMID: 39015422
PMC: 11250167.
DOI: 10.1002/hsr2.2250.
Diaz-Espada F, Matheu V, Barrios Y
Methods Microbiol. 2024; 50:189-222.
PMID: 38620993
PMC: 8919898.
DOI: 10.1016/bs.mim.2021.12.001.
Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine.
Picchianti-Diamanti A, Navarra A, Aiello A, Lagana B, Cuzzi G, Salmi A
Vaccines (Basel). 2023; 11(11).
PMID: 38006015
PMC: 10675674.
DOI: 10.3390/vaccines11111684.
Initial immune response after exposure to or to SARS-COV-2: similarities and differences.
Aiello A, Najafi-Fard S, Goletti D
Front Immunol. 2023; 14:1244556.
PMID: 37662901
PMC: 10470049.
DOI: 10.3389/fimmu.2023.1244556.
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.
Petrone L, Sette A, de Vries R, Goletti D
Pathogens. 2023; 12(7).
PMID: 37513709
PMC: 10385870.
DOI: 10.3390/pathogens12070862.
Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination.
Ishii T, Hamada K, Jubishi D, Hashimoto H, Okamoto K, Hisasue N
Sci Rep. 2023; 13(1):9607.
PMID: 37311763
PMC: 10263378.
DOI: 10.1038/s41598-023-36397-6.
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose.
Ruggieri S, Aiello A, Tortorella C, Navarra A, Vanini V, Meschi S
Int J Mol Sci. 2023; 24(10).
PMID: 37239872
PMC: 10218688.
DOI: 10.3390/ijms24108525.
Assessing SARS-CoV-2-specific T-cell reactivity in late convalescents and vaccinees: Comparison and combination of QuantiFERON and activation-induced marker assays, and relation with antibody status.
Gatti A, Zizzo G, De Paschale M, Tamburello A, Castelnovo L, Faggioli P
PLoS One. 2023; 18(5):e0285728.
PMID: 37220145
PMC: 10204942.
DOI: 10.1371/journal.pone.0285728.
Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity.
Dourdouna M, Tatsi E, Syriopoulou V, Michos A
Diagn Microbiol Infect Dis. 2023; 106(3):115948.
PMID: 37094435
PMC: 10060202.
DOI: 10.1016/j.diagmicrobio.2023.115948.
Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection.
Najafi-Fard S, Aiello A, Navarra A, Cuzzi G, Vanini V, Migliori G
Int J Infect Dis. 2023; 130 Suppl 1:S34-S42.
PMID: 36944383
PMC: 10027657.
DOI: 10.1016/j.ijid.2023.03.021.
An optimized flow cytometry protocol for simultaneous detection of T cell activation induced markers and intracellular cytokines: Application to SARS-CoV-2 immune individuals.
Altosole T, Rotta G, Uras C, Bornheimer S, Fenoglio D
J Immunol Methods. 2023; 515:113443.
PMID: 36842524
PMC: 9957341.
DOI: 10.1016/j.jim.2023.113443.
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.
Aiello A, Coppola A, Ruggieri S, Farroni C, Altera A, Salmi A
J Neurol Neurosurg Psychiatry. 2022; 94(4):290-299.
PMID: 36522154
PMC: 10086471.
DOI: 10.1136/jnnp-2022-330175.
Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy.
Najafi-Fard S, Petruccioli E, Farroni C, Petrone L, Vanini V, Cuzzi G
Front Immunol. 2022; 13:984098.
PMID: 36148228
PMC: 9486547.
DOI: 10.3389/fimmu.2022.984098.
Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave.
Aiello A, Grossi A, Meschi S, Meledandri M, Vanini V, Petrone L
Front Immunol. 2022; 13:920227.
PMID: 35967321
PMC: 9364317.
DOI: 10.3389/fimmu.2022.920227.
Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4 and CD8 T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay.
Aiello A, Coppola A, Vanini V, Petrone L, Cuzzi G, Salmi A
Int J Infect Dis. 2022; 122:841-849.
PMID: 35878802
PMC: 9307287.
DOI: 10.1016/j.ijid.2022.07.049.
MMF/MPA Is the Main Mediator of a Delayed Humoral Response With Reduced Antibody Decline in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.
Stumpf J, Siepmann T, Schwobel J, Glombig G, Paliege A, Steglich A
Front Med (Lausanne). 2022; 9:928542.
PMID: 35872777
PMC: 9300891.
DOI: 10.3389/fmed.2022.928542.
Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19.
Blanas A, Karsjens H, de Ligt A, Huijbers E, van Loon K, Denisov S
iScience. 2022; 25(8):104719.
PMID: 35813877
PMC: 9252865.
DOI: 10.1016/j.isci.2022.104719.
